A team at Japan's Shibaura Institute of Technology has synthesized a new form of vitamin K that pushes neural stem cells to mature into functioning neurons roughly three times more powerfully than the natural vitamin — a step that could change how doctors think about treating Alzheimer's, Parkinson's, and other neurodegenerative diseases.
The research, led by Associate Professor Yoshihisa Hirota and Professor Yoshitomo Suhara of the Department of Bioscience and Engineering, was published in ACS Chemical Neuroscience and received fresh international attention this week after being highlighted across science news outlets including ScienceDaily on May 27, 2026.
Why this matters
Diseases like Alzheimer's, Parkinson's, and Huntington's slowly destroy neurons — the cells that carry signals through the brain and nervous system. Current medications can ease symptoms, and the newest Alzheimer's drugs such as lecanemab and donanemab can modestly slow decline. But none of them rebuild what has been lost. The Shibaura team is chasing a more ambitious goal: helping the brain replace neurons that disease has stripped away.
Vitamin K is best known for keeping blood clotting properly and bones strong. Over the past decade, however, scientists have also tied it to the protection of brain cells and to neuronal differentiation, the process by which an immature neural cell commits to becoming a neuron. The most active natural form, menaquinone-4 (MK-4), already nudges this process along — but not enough to be useful as a medicine.
A more powerful molecule
To amplify that natural effect, the Japanese team designed 12 hybrid vitamin K molecules. Several were chemically linked to retinoic acid, an active form of vitamin A that is independently known to drive neuronal development. Others added a carboxylic acid group or a methyl ester side chain. The researchers then dropped each one onto mouse neural progenitor cells and measured how strongly the cells turned into neurons.
Vitamin K and retinoic acid work through different molecular pathways: vitamin K acts through the steroid and xenobiotic receptor (SXR), while retinoic acid acts through the retinoic acid receptor (RAR). The new hybrids preserved both signals at once.
One candidate stood out. Combining the retinoic acid structure with a methyl ester side chain, it produced about three times the level of microtubule associated protein 2 (Map2) — a key marker of growing neurons — compared with the standard compound. The team has named it Novel VK.
"The newly synthesized vitamin K analogues demonstrated approximately threefold greater potency in inducing the differentiation of neural progenitor cells into neurons compared to natural vitamin K," Dr. Hirota said. "Since neuronal loss is a hallmark of neurodegenerative diseases such as Alzheimer's disease, these analogues may serve as regenerative agents that help replenish lost neurons and restore brain function."
What comes next
The work is still at the cell-culture stage, and a long road of animal testing and clinical trials lies between Novel VK and any future medicine. But the result is meaningful for two reasons. First, it suggests that the brain's capacity to grow new neurons can be coaxed by familiar nutrients tuned into more potent shapes — rather than by exotic, hard-to-deliver biologics. Second, it points to a category of therapies that might eventually do something today's drugs cannot: not just slow neurodegeneration, but help reverse it.
Vitamin K already has a clean safety record at normal doses, which gives the analogue program a friendlier starting point than many novel compounds. The Shibaura team is now exploring how Novel VK behaves in living tissue and how it might be formulated for delivery to the brain.
If the work continues to translate, a vitamin once filed under "good for blood and bones" could end up at the center of one of the toughest problems in medicine — and offer aging brains a real chance to rebuild.
